FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210752064> ?p ?o ?g. }

• W4210752064 abstract "Abstract Background Understanding the role of amyloid imaging in the earliest stages of Alzheimer’s Disease (AD) becomes increasingly relevant for secondary prevention. In this context, the AMYPAD Prognostic and Natural History Study (PNHS) is an open‐label, prospective, multi‐centre cohort study ( http://amypad.eu/ ) to determine the value of quantitative amyloid PET imaging in determining AD dementia risk. The study recruits from several European cohorts and aims at enrolling 2000 non‐demented individuals with a particular focus on those with emerging amyloid pathology. Method As of January 25 th , 2020, AMYPAD PNHS had 17 actively recruiting sites across Europe, and 782 non‐demented participants (>95% cognitively unimpaired) had consented to participate in the study. Of those, 448 are from EPAD LCS, 129 from EMIF‐AD Twin 60++, 111 from FACEHBI, 70 from ALFA+, 17 from FPACK, and 7 from the UCL‐2010‐412 cohort. Of the consented subjects, 334 already had an amyloid PET scan before this study. Within AMYPAD PNHS, 588 subjects have hitherto been scanned with either [ 18 F]flutemetamol or [ 18 F]florbetaben. Of note, 53.6% of the total number of scans have been acquired with a dual‐time window dynamic protocol. The primary outcome measure is the Centiloid value (CL) using the whole cerebellum as reference region, to enable quantitative comparability between the two tracers in the study. Also, images have been visually assessed by local raters. Of the 588 acquired scans, 296 have been quantified with IXICO’s LEAP pipeline and passed Quality Control, thus rendering valid CL values. Subjects were categorized as amyloid‐negative (CL≤12); as in a “gray‐zone” (12<CL≤50) or amyloid‐positive (CL>50) and a Gaussian Mixture Model was used to assess the population’s Centiloid distribution. Result Based on visual assessment, 28% of the fully 296 quantified scans were visually rated as positive and 72% as negative. Quantitatively, 50% of them were categorized as negative, 33% in the gray‐zone, and 17% were positive (Figure 1). Centiloid values ranged from ‐30.3 to 154.2 (Mean±SD: 22.5±32.0 CL) (Figure 2). Conclusion Preliminary quantitative results indicate that PNHS is being successful in recruiting a cohort mostly composed of cognitively unimpaired individuals who are enriched for early amyloid abnormalities, which is the intended target population." @default.
• W4210752064 created "2022-02-08" @default.
• W4210752064 creator A5000884161 @default.
• W4210752064 creator A5011414875 @default.
• W4210752064 creator A5013384493 @default.
• W4210752064 creator A5014248780 @default.
• W4210752064 creator A5020794941 @default.
• W4210752064 creator A5021075936 @default.
• W4210752064 creator A5026262571 @default.
• W4210752064 creator A5029875703 @default.
• W4210752064 creator A5033361414 @default.
• W4210752064 creator A5036068671 @default.
• W4210752064 creator A5037622152 @default.
• W4210752064 creator A5039782136 @default.
• W4210752064 creator A5040673262 @default.
• W4210752064 creator A5045793605 @default.
• W4210752064 creator A5046266581 @default.
• W4210752064 creator A5049484291 @default.
• W4210752064 creator A5050002274 @default.
• W4210752064 creator A5050897246 @default.
• W4210752064 creator A5051868596 @default.
• W4210752064 creator A5055524428 @default.
• W4210752064 creator A5059793455 @default.
• W4210752064 creator A5063066226 @default.
• W4210752064 creator A5066508710 @default.
• W4210752064 creator A5068609987 @default.
• W4210752064 creator A5069686312 @default.
• W4210752064 creator A5071341444 @default.
• W4210752064 creator A5075804608 @default.
• W4210752064 creator A5075964502 @default.
• W4210752064 creator A5076043002 @default.
• W4210752064 creator A5076585111 @default.
• W4210752064 creator A5079528229 @default.
• W4210752064 creator A5083763339 @default.
• W4210752064 creator A5084573677 @default.
• W4210752064 creator A9999999999 @default.
• W4210752064 date "2021-12-01" @default.
• W4210752064 modified "2023-10-18" @default.
• W4210752064 title "Current status and quantitative results of the AMYPAD prognostic and natural history study" @default.
• W4210752064 doi "https://doi.org/10.1002/alz.055540" @default.
• W4210752064 hasPublicationYear "2021" @default.
• W4210752064 type Work @default.
• W4210752064 citedByCount "0" @default.
• W4210752064 crossrefType "journal-article" @default.
• W4210752064 hasAuthorship W4210752064A5000884161 @default.
• W4210752064 hasAuthorship W4210752064A5011414875 @default.
• W4210752064 hasAuthorship W4210752064A5013384493 @default.
• W4210752064 hasAuthorship W4210752064A5014248780 @default.
• W4210752064 hasAuthorship W4210752064A5020794941 @default.
• W4210752064 hasAuthorship W4210752064A5021075936 @default.
• W4210752064 hasAuthorship W4210752064A5026262571 @default.
• W4210752064 hasAuthorship W4210752064A5029875703 @default.
• W4210752064 hasAuthorship W4210752064A5033361414 @default.
• W4210752064 hasAuthorship W4210752064A5036068671 @default.
• W4210752064 hasAuthorship W4210752064A5037622152 @default.
• W4210752064 hasAuthorship W4210752064A5039782136 @default.
• W4210752064 hasAuthorship W4210752064A5040673262 @default.
• W4210752064 hasAuthorship W4210752064A5045793605 @default.
• W4210752064 hasAuthorship W4210752064A5046266581 @default.
• W4210752064 hasAuthorship W4210752064A5049484291 @default.
• W4210752064 hasAuthorship W4210752064A5050002274 @default.
• W4210752064 hasAuthorship W4210752064A5050897246 @default.
• W4210752064 hasAuthorship W4210752064A5051868596 @default.
• W4210752064 hasAuthorship W4210752064A5055524428 @default.
• W4210752064 hasAuthorship W4210752064A5059793455 @default.
• W4210752064 hasAuthorship W4210752064A5063066226 @default.
• W4210752064 hasAuthorship W4210752064A5066508710 @default.
• W4210752064 hasAuthorship W4210752064A5068609987 @default.
• W4210752064 hasAuthorship W4210752064A5069686312 @default.
• W4210752064 hasAuthorship W4210752064A5071341444 @default.
• W4210752064 hasAuthorship W4210752064A5075804608 @default.
• W4210752064 hasAuthorship W4210752064A5075964502 @default.
• W4210752064 hasAuthorship W4210752064A5076043002 @default.
• W4210752064 hasAuthorship W4210752064A5076585111 @default.
• W4210752064 hasAuthorship W4210752064A5079528229 @default.
• W4210752064 hasAuthorship W4210752064A5083763339 @default.
• W4210752064 hasAuthorship W4210752064A5084573677 @default.
• W4210752064 hasAuthorship W4210752064A9999999999 @default.
• W4210752064 hasConcept C126322002 @default.
• W4210752064 hasConcept C142724271 @default.
• W4210752064 hasConcept C151730666 @default.
• W4210752064 hasConcept C15744967 @default.
• W4210752064 hasConcept C163276114 @default.
• W4210752064 hasConcept C188816634 @default.
• W4210752064 hasConcept C201903717 @default.
• W4210752064 hasConcept C2778279407 @default.
• W4210752064 hasConcept C2779134260 @default.
• W4210752064 hasConcept C2779343474 @default.
• W4210752064 hasConcept C2779483572 @default.
• W4210752064 hasConcept C71924100 @default.
• W4210752064 hasConcept C72563966 @default.
• W4210752064 hasConcept C86803240 @default.
• W4210752064 hasConceptScore W4210752064C126322002 @default.
• W4210752064 hasConceptScore W4210752064C142724271 @default.
• W4210752064 hasConceptScore W4210752064C151730666 @default.
• W4210752064 hasConceptScore W4210752064C15744967 @default.
• W4210752064 hasConceptScore W4210752064C163276114 @default.
• W4210752064 hasConceptScore W4210752064C188816634 @default.
• W4210752064 hasConceptScore W4210752064C201903717 @default.
• W4210752064 hasConceptScore W4210752064C2778279407 @default.

• next